The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia
Phase of Trial: Phase IV
Latest Information Update: 12 Jul 2019
Price : $35 *
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
- Indications Hypoglycaemia; Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms HypoDeg
- 26 Jun 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 03 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Apr 2019.